susceptibility

[키워드] active treatment phase Amiodarone anticipated Arm ARMS assessment baseline blinded Block randomisation block size Blood Group Breastfeeding Cambridge Care Chemoprophylaxis Chloroquine Chronic kidney disease ciprofloxacin clarithromycin clinical clinical testing Compliance Contact coronavirus disease COVID-19 COVID-19 case COVID-19 disease COVID-19 disease severity COVID-19 infection COVID-19 patients criteria current cyclosporin Daily Daily-dosing Date Day deficiency defined described determine diagnosed with COVID-19 Diagnosis digoxin disease dissemination dose dosed element enrolled enrolment epilepsy EU Clinical Trial EudraCT evaluated Factor File fluconazole Follow-up foundation frontline healthcare workers G6PD Genetic Glucose-6-phosphate halofantrine HCQ healthcare Healthcare workers heart failure hospital Hydroxychloroquine hypersensitivity reaction increase Infection Intervention investigator Laboratory Liver disease maintenance Matched mefloquine moxifloxacin National Health Service NHS number objective oral outcome participant Participants Patient patients with COVID-19 pharmacokinetic phase Placebo placebo tablet placebo-controlled trial porphyria positive COVID-19 positive individual Positive test Praziquantel predicted Prevent problem prochlorperazine protocol randomised randomised controlled trial recruited recruitment regimen Registered reported Research Retinal disease Sample size Secondary objective serology serum biomarker Standard statistical analysis status Stratification stratified Study protocol susceptibility symptoms onset syndrome table Tablet tablets time Treatment treatment period Trial Trust university Variation website Weekly Weekly-dosing work
[DOI] 10.1186/s13063-020-04543-4 PMC 바로가기 [Article Type] Letter